Nitrosamine impurity analysis in active pharmaceutical ingredients (APIs) has become a critical regulatory priority since the 2018 discovery of N-nitrosodimethylamine (NDMA) in sartan-class drugs triggered worldwide recalls. Accredited third-party laboratories now provide ultra-trace detection of nitrosamine impurities at parts-per-billion (ppb) levels using advanced GC-MS/MS, LC-MS/MS, and high-resolution mass spectrometry platforms. This article outlines the sources, testing scope, analytical methods, and regulatory framework governing nitrosamine control in pharmaceutical manufacturing.
Technical Overview
Nitrosamines are a class of probable human carcinogens belonging to the cohort of concern defined in ICH M7(R2), the internationally harmonized guideline for the assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals. Since authorities first detected N-nitrosodimethylamine (NDMA) in valsartan in 2018, nitrosamine contamination has led to extensive recalls of sartans, ranitidine, nizatidine, metformin, rifampicin, and numerous other drug products across global markets.
Nitrosamine formation in APIs typically occurs through the unintended reaction of secondary, tertiary, or quaternary amines with nitrosating agents such as nitrite salts, nitrogen oxides, or nitrosyl species under acidic conditions. Additional root causes include contaminated recycled solvents, nitrite-bearing raw materials, sodium nitrite used as a quenching agent, degradation during storage, and nitrosamine transfer from packaging components such as blister foils and elastomeric closures.
Because acceptable daily intakes for nitrosamines are extremely low, for example 96 ng/day for NDMA and 26.5 ng/day for NDEA as established by regulatory authorities, analytical methods must achieve quantification limits in the low ppb range relative to the maximum daily dose of the drug substance. The regulatory landscape now also encompasses nitrosamine drug substance-related impurities (NDSRIs), which are nitrosated derivatives of the API itself and must be evaluated under the expanded control strategies published by major health authorities.
Testing Samples
Sartan-Class APIs (Angiotensin II Receptor Blockers)
Tetrazole-containing sartans such as valsartan, irbesartan, losartan potassium, olmesartan medoxomil, and candesartan cilexetil represent the highest-risk category because their synthesis historically employed nitrite-containing azide chemistry. Both the APIs and their intermediates are routinely submitted for nitrosamine screening.
Histamine H2 Receptor Antagonist APIs
Ranitidine and nizatidine drug substances are prone to NDMA formation through intrinsic instability of the dimethylamine moiety, requiring testing of both freshly manufactured material and samples held under accelerated stability conditions.
Biguanide and Other High-Volume APIs
Metformin hydrochloride, rifampicin, rifapentine, and any API containing a vulnerable secondary amine or dimethylamine group in its structure should be evaluated for nitrosamine risk, including potential formation of NDSRIs.
Upstream Materials and Process Streams
Testing scope extends to starting materials, intermediates, reagents, catalysts, fresh and recovered solvents, process water, and packaging contact materials in order to map the complete nitrosamine risk profile of a manufacturing process.
Testing Items
Comprehensive nitrosamine testing programs target the full panel of small-molecule nitrosamines specified in current regulatory guidance, alongside compound-specific NDSRIs:
- NDMA (N-nitrosodimethylamine) with an acceptable intake of 96 ng/day
- NDEA (N-nitrosodiethylamine) with an acceptable intake of 26.5 ng/day
- NMBA (N-nitroso-N-methyl-4-aminobutyric acid) with an acceptable intake of 96 ng/day
- NEIPA (N-nitrosoethylisopropylamine) with an acceptable intake of 96 ng/day
- NDIPA (N-nitrosodiisopropylamine) with an acceptable intake of 96 ng/day
- NDBA (N-nitrosodibutylamine) with an acceptable intake of 96 ng/day
- NMPA (N-nitrosomethylphenylamine) with an acceptable intake of 34.3 ng/day
- NDPA (N-nitrosodipropylamine) and N-nitrosomorpholine as supplementary targets
- NDSRIs (nitrosamine drug substance-related impurities) specific to each API structure
- Total nitrosamine content and nitrite residue screening as supporting measurements
Reportable results are compared against the permissible concentration in the API, which is calculated from the acceptable daily intake divided by the maximum daily dose of the drug product.
Testing Methods
Method selection depends on the volatility, polarity, and thermal stability of the target nitrosamines, with confirmatory testing typically performed using two orthogonal techniques:
- Headspace GC-MS/MS with negative chemical ionization or electron impact ionization for volatile nitrosamines such as NDMA, NDEA, NEIPA, and NDIPA, delivering sub-ppb detection limits
- Liquid injection GC-MS/MS for semi-vatile nitrosamines and confirmation of headspace results
- LC-MS/MS with triple quadrupole detection in multiple reaction monitoring mode for non-volatile and thermally labile nitrosamines such as NMBA and most NDSRIs
- LC-HRMS using QTOF or Orbitrap platforms for unknown nitrosamine screening, structural elucidation, and NDSRI identification
- Ion chromatography or spectrophotometric nitrite determination as a root-cause screening tool
All quantitative methods are validated in accordance with ICH Q2(R2) requirements covering specificity, linearity, accuracy, precision, detection limit, quantification limit, range, and robustness, with typical LOQ values of 0.03 ppm or lower. Compendial procedures such as USP General Chapter <1469> and Ph. Eur. general method 2.5.42 provide the recognized reference framework, and accredited third-party laboratories operate under ISO/IEC 17025 quality systems to ensure data integrity and regulatory acceptance.
Applications
Nitrosamine impurity analysis supports multiple stages of the pharmaceutical lifecycle:
- Regulatory submissions responding to health authority requests for confirmatory testing data and risk assessment documentation
- Three-stage risk assessments covering manufactured products, products in development, and products under authorization, as defined in current agency guidance
- Batch release testing and routine commercial quality control where nitrosamines are specified impurities
- Process development studies evaluating the effect of nitrite levels, pH, temperature, amine structure, and quenching sequences on nitrosamine formation
- Stability programs assessing nitrosamine growth over time under long-term, intermediate, and accelerated storage conditions
- Root cause investigations, supplier qualification, recovered solvent monitoring, and CAPA verification following out-of-specification findings
- Packaging compatibility studies examining nitrosamine migration from blister foils, lids, and closures
FAQ
Why must nitrosamine testing reach ppb-level sensitivity?
Acceptable daily intakes for nitrosamines range from roughly 18 to 96 ng/day depending on the compound. For a high-dose drug taken at 2 grams per day, the corresponding permissible concentration in the API may fall below 0.05 ppm, so methods must reliably quantify at concentrations an order of magnitude below traditional impurity limits.
Which APIs are considered at highest risk of nitrosamine contamination?
APIs synthesized with nitrite or nitrous acid in the presence of secondary amines, tetrazole-ring sartans produced via azide chemistry, APIs containing dimethylamine or other vulnerable amine groups, and products using recovered solvents or nitrite-contaminated excipients carry the greatest risk and warrant priority testing.
What is the difference between small-molecule nitrosamines and NDSRIs?
Small-molecule nitrosamines such as NDMA and NDEA are low molecular weight contaminants unrelated to the API structure, while NDSRIs are formed when the API molecule itself, or a structurally related amine fragment, undergoes nitrosation. NDSRIs require API-specific analytical methods and compound-specific acceptable intakes calculated from structure-activity relationships.
How should manufacturers structure a nitrosamine control strategy?
A robust strategy combines risk assessment of the entire synthesis route and supply chain, confirmatory testing by validated methods, product-specific limits derived from acceptable daily intakes, process controls that minimize nitrosating conditions, appropriate specifications, and ongoing monitoring through stability and routine release testing in line with ICH M7(R2) principles.
Can nitrosamines form during storage or analysis?
Yes. Certain APIs such as ranitidine can form NDMA during storage, particularly at elevated temperature and humidity, and artifactual formation can occur during sample preparation if amines coexist with nitrite under acidic conditions. Laboratories apply controlled extraction conditions, amine scavengers, and rapid analysis sequences to suppress false positives.